Skip to content
Screener

Nurix Therapeutics, Inc. NRIX Business Segments — R&D

Similar metrics at other companies

Veradermics logo
MANEReportable Segment — R&D
$17.19M+85.3%
Zscaler logo
ZSReportable Segment — R&D
$143.5M+35.4%
Snowflake logo
SNOWReportable Segment — R&D
$534.94M+13.2%
Veeva Systems logo
VEEVReportable Segment — R&D
$156.76M+15.2%
Bicara Therapeutics logo
BCAXReportable Segment — R&D
$47.5M+38.4%
Silicon Laboratories logo
SLABReportable Segment — R&D
$88.59M+0.4%

Other financials

Income statement

See full
Revenue$9.0M-79.5%
Operating income-$94.2M-95.0%
Net income-$89.5M-106%
EPS (diluted)-$0.81-55.8%

Balance sheet

See full
Cash & equivalents$68.7M-19.4%
Total debt$58.1M+12.0%
Total equity$402.6M-10.0%
Total assets$535.5M-9.5%

Cash flow

See full
Operating cash flow-$96.6M-52.9%
CapEx$1.9M-27.6%
Free cash flow-$98.5M-49.6%

Valuation

See full
Market cap$2.62B+227%
Enterprise value$2.61B+240%
P/S71.2×+62.1×

Profitability

See full
Operating margin-982.4%-1,538pp
Net margin-928.4%-1,403pp
FCF margin-378.7%+24.1pp

Returns & leverage

See full
Return on equity-80.3%+113pp
Debt / equity0.1×0.0×
Current ratio6.3×-0.5×

Where this comes from

Reported directly by Nurix Therapeutics, Inc. in its filing.

Tagged under the XBRL concept us-gaap:ResearchAndDevelopmentExpense.

The source filing: Nurix Therapeutics, Inc.’s 10-Q, filed July 9, 2026.

Filed
Jul 9, 2026, 4:12 PM EDT
Fiscal quarter
Q2 FY2026
Calendar quarter
Q2 2026
Accession
0001549595-26-000040
Line itemThree Months Ended May 31, 2026Three Months Ended May 31, 2025Six Months Ended May 31, 2026Six Months Ended May 31, 2025
External clinical development expenses:
Bexobrutideg (NX-5948)$28,192$18,558$52,166$34,278
Zelebrudomide (NX-2127)1,1671,5593,0732,665
NX-16071,7382,3322,9264,292
Internal research and development expenses56,55655,647113,624106,524
Total research and development expenses$87,653$78,096$171,789$147,759

Item 1. Financial Statements (Unaudited)

FAQ

What is Nurix Therapeutics, Inc.'s business segments — R&D?
Nurix Therapeutics, Inc. (NRIX) reported business segments — R&D of $87.65M in Q1 2026.
How has Nurix Therapeutics, Inc.'s business segments — R&D changed year-over-year?
Nurix Therapeutics, Inc.'s business segments — R&D increased by 12.2% year-over-year, from $78.1M to $87.65M.
What does business segments — R&D mean?
This metric represents the total operating expenses dedicated to the discovery and clinical development of novel therapeutic candidates within the company's primary business segment. It encompasses costs associated with laboratory research, preclinical studies, and clinical trial execution for the company's protein modulation pipeline. Monitoring this expenditure provides insight into the company's commitment to advancing its drug development portfolio and its long-term investment in future revenue-generating assets.

Ask your AI about Nurix Therapeutics, Inc.'s business segments — r&d.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude